🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Ipca Laboratories Limited IPCALAB NIFTY_MIDNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.ipca.com

Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.

READ MORE ›
₹1,524.40
+3.84% 1Y

Market & Price

Market Cap
₹38,674.67 Cr
Current Price
₹1,524.40
High / Low (52W)
₹1,656.20 / ₹1,268.70
Beta
-

Valuation

Stock P/E
33.90
Industry PE
37.60
Forward P/E
23.57
PEG Ratio
-
Book Value
₹324.60
Price to Book
4.70
P/S
3.94
EV/EBITDA
18.46
Dividend Yield
0.39%

Profitability & Returns

ROCE
16.38%
ROE
13.22%
ROA
8.99%
Profit Margin
11.62%
Op Margin
18.95%
EPS (Latest Qtr)
₹11.79
EPS (TTM)
₹44.97

Balance Sheet & Liquidity

Debt/Equity
0.08
Quick Ratio
1.39
Current Ratio
2.76
Debt
₹808.76 Cr
Total Assets
₹12,370.19 Cr
Current Assets
₹6,373.61 Cr
Working Capital
₹4,066.68 Cr

Ownership

Promoter Holding
45.08%
Chg in Prom Hold
-
FII / Inst Holding
45.35%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹39,739.56 Cr
Total Revenue (TTM)
₹9,820.78 Cr
EBITDA
₹2,153.01 Cr
Free Cash Flow
₹860.21 Cr
Operating Cash Flow
₹1,141.97 Cr
Shares Outstanding
₹25.37 Cr
Gross Margin
71.26%
Payout Ratio
4.45%

Growth (CAGR)

Revenue 5Y
15.83%
Profit 5Y
34.28%
Revenue (YoY)
10.40%
Earnings (YoY)
341.60%

PROS

  • Compounding revenue at 15.8% over 5 years.
  • Profit CAGR of 34.3% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 IPCALAB Ipca Laboratories Limited NIFTY_MIDNSEPHARMA 1,524.40 33.90 ₹38,674.67 Cr 0.39% 16.38% 13.22% 15.83% 34.28%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --2,246.69 Cr2,308.85 Cr2,556.50 Cr2,392.50 Cr2,388.48 Cr
Cost of Revenue --708.29 Cr691.56 Cr781.64 Cr657.90 Cr691.62 Cr
Gross Profit --1,538.40 Cr1,617.29 Cr1,774.86 Cr1,734.60 Cr1,696.86 Cr
Operating Expenses --1,209.66 Cr1,300.93 Cr1,333.27 Cr1,308.84 Cr1,320.13 Cr
Operating Income --328.74 Cr316.36 Cr441.59 Cr425.76 Cr376.73 Cr
EBITDA --249.63 Cr449.08 Cr514.52 Cr571.19 Cr531.79 Cr
Interest Expense --21.51 Cr18.51 Cr19.61 Cr17.62 Cr20.20 Cr
Pretax Income --128.00 Cr330.51 Cr391.58 Cr445.98 Cr404.45 Cr
Tax Provision --62.22 Cr96.09 Cr108.08 Cr81.93 Cr95.05 Cr
Net Income --67.82 Cr233.21 Cr282.57 Cr326.27 Cr299.07 Cr
Diluted EPS --2.679.1911.1412.8611.79

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -6,206.85 Cr7,622.41 Cr8,939.59 Cr9,646.33 Cr
Cost of Revenue -2,407.51 Cr2,725.79 Cr2,778.55 Cr2,822.72 Cr
Gross Profit -3,799.34 Cr4,896.62 Cr6,161.04 Cr6,823.61 Cr
Operating Expenses -3,094.58 Cr3,962.15 Cr4,832.72 Cr5,263.17 Cr
Operating Income -704.76 Cr934.47 Cr1,328.32 Cr1,560.44 Cr
EBITDA -1,051.94 Cr1,337.20 Cr1,613.89 Cr2,066.58 Cr
Interest Expense -45.09 Cr137.29 Cr84.93 Cr75.94 Cr
Pretax Income -745.29 Cr842.67 Cr1,131.14 Cr1,572.52 Cr
Tax Provision -253.36 Cr313.46 Cr343.61 Cr381.15 Cr
Net Income -471.32 Cr547.35 Cr737.68 Cr1,141.12 Cr
Diluted EPS 34.8518.5821.5729.08-

Compounded Sales Growth

5 Years:15.83%
1 Year:10.40%

Compounded Profit Growth

5 Years:34.28%
1 Year:341.60%

Stock Price Performance

1 Year:+3.84%
6 Months:+6.74%
3 Months:+0.60%
1 Month:-0.42%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -8,626.43 Cr11,101.28 Cr11,760.55 Cr12,370.19 Cr
Current Assets -5,189.27 Cr5,538.90 Cr6,268.54 Cr6,373.61 Cr
Cash & Equivalents -1,257.85 Cr208.91 Cr167.17 Cr437.12 Cr
Inventory -1,743.37 Cr2,471.31 Cr2,560.42 Cr2,731.00 Cr
Receivables -989.02 Cr1,686.51 Cr1,873.82 Cr2,014.26 Cr
Total Liabilities -2,711.11 Cr3,374.28 Cr3,372.28 Cr2,846.13 Cr
Current Liabilities -1,805.82 Cr2,355.64 Cr2,386.22 Cr2,306.93 Cr
Long Term Debt -651.78 Cr580.41 Cr543.24 Cr109.12 Cr
Total Debt -1,481.27 Cr1,438.36 Cr1,362.74 Cr808.76 Cr
Total Equity -5,842.02 Cr6,332.19 Cr6,948.45 Cr8,063.81 Cr
Shares Outstanding -25.37 Cr25.37 Cr25.37 Cr25.37 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -805.81 Cr944.65 Cr1,321.32 Cr1,141.97 Cr
Investing Cash Flow --725.00 Cr-1,291.79 Cr-869.50 Cr-246.77 Cr
Financing Cash Flow -507.24 Cr-552.55 Cr-282.98 Cr-753.52 Cr
Capital Expenditure --494.47 Cr-411.29 Cr-775.57 Cr-655.95 Cr
Free Cash Flow -311.34 Cr533.36 Cr545.75 Cr486.02 Cr
Net Change in Cash -588.05 Cr-899.69 Cr168.84 Cr141.68 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -61.2%64.2%68.9%70.7%
Operating Margin % -11.4%12.3%14.9%16.2%
Net Margin % -7.6%7.2%8.3%11.8%
ROE % -8.1%8.6%10.6%14.2%
ROCE % -10.3%10.7%14.2%15.5%

Shareholding Pattern

Insiders
45.08%
Institutions
45.35%
Public Float
82.58%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for IPCALAB

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space